Wacker gets FDA approval make drug substance in Chiesi's Retavase

Wacker gets FDA approval to make drug substance in Chiesi's Retavase

6:31 AM, 12th January 2018
Wacker logo

MUNICH/ HALLE, GERMANY: Wacker Biotech GmbH said that it will produce the drug substance reteplase, the active ingredient in the drug Retavase, which the pharmaceutical company Chiesi will market in the US.

The product recently obtained approval from the US Food and Drug Administration (FDA). The medication is used to treat acute myocardial infarction in adults. Wacker Biotech has successfully transferred and implemented the entire manufacturing process for reteplase to its GMP plant in Halle/Saale (Germany). It already obtained approval from the European Medicines Agency (EMA) in 2012.

In agreement with the original manufacturer of the medication – Swiss pharmaceutical company Roche – Wacker Biotech successfully transferred the production process of the drug substance reteplase to its Halle/Saale plant.

Chiesi has acquired the marketing rights for the drug for the US, among other countries, and worked on obtaining the new approval in close cooperation with Wacker. Not only did Wacker successfully transfer the entire manufacturing process for the complex biopharmaceutical to its facility, it also covered the validation of the analytical methods for process control and release testing of the drug substance. In close cooperation with customer Chiesi, Wacker established the supply of this high-quality drug substance for Chiesi's relaunch of Retavase in US market.

Wacker Biotech obtained approval for the commercial manufacture of the active ingredient for the US market a mere three months after the FDA inspection of the plant in Halle. The reliable process in a modern facility now provides an efficient, secure supply of medication for patients.

The drug Retavase used to treat acute ST-elevation myocardial infarction (STEMI). Acute STEMI, also known as acute heart attack, is one of the main causes of death and illness worldwide and, in most cases, stems from a blood clot in a coronary artery. This sustained circulatory disorder prevents oxygen and nutrients from getting to the heart and thus results in tissue dying off and long-term damage to the heart muscle. When administered to acute STEMI patients, the enzyme reteplase – a tissue plasminogen activator with twelve disulfide bridges that is folded in a complex manner – causes these blood clots to dissolve.

“We are very pleased with the FDA approval of Chiesi’s product Retavase for the US market. This allows us, as a contract manufacturer, to contribute to the treatment of serious illnesses such as a heart attack,” said Dr Susanne Leonhartsberger, managing director of Wacker Biotech.

“This approval represents a significant milestone in Chiesi’s work to bring Retavase back to the US market. Wacker is a proven leader in microbial technology. The collaborative effort and partnership have been outstanding,” said Alan Roberts, senior vice president, scientific affairs for Chiesi USA Inc.

© Chemical Today News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Toward a smart graphene membrane to desalinate water

An international team of researchers, including scientists from Shinshu University (Japan) and the director of Penn State’s ATOMIC Center, has d ...

Read more
Devan launches new product line – revitalizing skin via textiles

RONSE, BELGIUM: Devan Chemicals, a developer of finishing technologies for textiles, has launched a new product line. These revitalizing agents e ...

Read more
Reducing power plants’ freshwater consumption

Power plants draw more freshwater than any other consumer in the US, accounting for more than 50 percent of the nation’s freshwater use at about ...

Read more
One-step 3D printing of catalysts developed

The US Department of Energy’s Ames Laboratory has developed a 3D printing process that creates a chemically active catalytic object in a single ...

Read more
Common ‘oxygen sponge’ catalyst soaks up hydrogen too

Having the right tool for the job enabled scientists at the Department of Energy’s Oak Ridge National Laboratory and their collaborators to disc ...

Read more
Honeywell unveils Cloud Historian as part of its connected plant

HOUSTON, US: Honeywell Process Solutions (HPS) has launched its Honeywell connected plant Uniformance Cloud Historian. This new offering is ...

Read more